Cantor Fitzgerald Reiterates TherapeuticsMD (TXMD) at Overweight, $5 PT, VitaCare Sale is Good News, Priced Above Expectation, Increases Confidence in the Stock
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $5.00 price target on TherapeuticsMD (NASDAQ: TXMD), following announcement of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
